Skip to main content

Talk Bio

Search This Blog

Greg Verdine's LifeMine raises $263M for safer immunosuppressant

on August 06, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

LifeMine Therapeutics, led by Greg Verdine, has raised a combined $263 million in Series D and E financing to advance LIFE-001, a next-generation calcineurin inhibitor for organ transplant rejection.

The $263M comprises a $75M Series D (closed in Q4 2025) and an oversubscribed $188M Series E led by Milky Way Investments, with new investors including Bezos Expeditions, Gates Frontier, and RA Capital Management, plus continued backing from GSK, ARCH Venture Partners, GV, and others.

LIFE-001 is a direct calcineurin activation inhibitor discovered from fungal genomes that aims to replace toxic legacy immunosuppressants like tacrolimus and cyclosporine, preserving efficacy while reducing multiorgan toxicity.

Sources:

LifeMine raises $263M in mission to improve organ ...

LifeMine revived by $188M fundraise backed by Gates and ...

LifeMine Therapeutics Raises $263M in Watertown, MA

LifeMine raises $175 million, signs pact with GSK - C&EN

LifeMine Therapeutics Raises $263M to Advance Novel Calcineurin Inhibitor LIFE-001 for Organ Transplant Rejection

GSK partners with LifeMine as startups advance plans to ...

LifeMine Lands $55 Million Series A, Seeks New Drugs From Fungi

LifeMine raises $175m to find drugs from fungi - The Boston Globe

A scientist-turned-biotech executive is notching some wins, and enjoying it

LifeMine Therapeutics Announces $175 Million Series C Financing

LifeMine locks down $70M 'dream scenario' fungi ...

Recon: FDA approves first drug for type 1 narcolepsy, mRNA flu vaccine; No merger talks between AstraZeneca-BMS

Greg Verdine will have many new C-suite friends at fungus biotech LifeMine after GSK-fueled $175M round

Bezos Expeditions CABIN1 protein, human Gates Greg Verdine Immunosuppressive Agents LIFE-001 LifeMine Therapeutics methionine Milky Way Investments organ transplant rejection Series D Series E SmithKline Beecham

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

OKYO Pharma Appoints Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma announced on February 10, 2026, the appointment of Flavio Mantelli, MD, PhD, as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Dr. Mantelli previously served as CMO at Dompé, where he led the clinical development, FDA approval, and global strategy for Oxervate®, a blockbuster orphan drug with over $1 billion in sales in 2024. Urcosimod has FDA Fast Track designation for NCP, with a planned ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026. This appointment follows the recent hiring of CEO Robert Dempsey and strengthens OKYO's ophthalmology leadership team. OKYO Pharma shares rose 10.80% intraday following the announcement. Sources:

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Powered by Blogger

X-Data LLC